Venetoclax combined with azacitidine in treatment of myelodysplastic syndromes complicated with monoclonal globulinemia of unknown significance: report of 1 case and review of literature
10.3760/cma.j.cn115356-20210917-00224
- VernacularTitle:维奈克拉联合阿扎胞苷治疗骨髓增生异常综合征合并意义未明的单克隆球蛋白血症1例并文献复习
- Author:
Guangyang WENG
1
;
Haoyu PENG
;
Weiwen YOU
;
Huanxun LIU
;
Yun CAI
;
Xin DU
Author Information
1. 深圳市第二人民医院血液科，深圳 518000
- Keywords:
Myelodysplastic syndromes;
Monoclonal globulinemia of unknown significance;
Venetoclax;
Azacitidine;
t(11;
14)
- From:
Journal of Leukemia & Lymphoma
2022;31(11):680-683
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the therapeutic effect of venetoclax combined with azacitidine in treatment of myelodysplastic syndromes (MDS) complicated with monoclonal globulinemia of unknown significance (MGUS).Methods:The clinical data of a patient with MDS complicated with MGUS in the Second People's Hospital of Shenzhen in December 2020 were retrospectively analyzed, and the literatures were reviewed.Results:According to results of bone marrow smear, cytogenetics, and next-generation sequencing, the patient was diagnosed as MDS and MGUS complicated with ASXL1, RUNX1, EZH2, STAG2 mutations as well as t(11;14). No response was observed after 2 courses of azacitidine and 1 course of azacitidine plus HAG. Later the patient achieved complete remission and negative RUNX1 and STAG2 mutations after a course of venetoclax combined with azacitidine. Meanwhile, M protein exhibited a decrease more than 50%. To date, the patient was still in complete remission.Conclusions:The regimen of venetoclax combined with azacitidine shows a significant efficacy and good tolerance to patient with co-occurrence of MDS and MGUS with t(11; 14).
